Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2021-08-12 00:00:00 ET · period of report 2021-08-11 · accession 0001209191-21-051016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2021-08-12 | 2021-08-11 | KYMR | Booth Bruce | Dir | S - Sale | $61.00 | -242.1K | 0 | -100% | -$14.77M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-11 | S | D | 242,133 | $61.00 | 0 | I See footnote | — | — | (F1) The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), on May 18, 2021, for no additional consideration to its limited partners and its general partner, Atlas Venture Associates X, L.P. ("AVA X LP"), subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16. (F2) These shares are held directly by AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any. |